Volume 73, Issue 5, Pages 696-703 (May 2018) Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial  Pernelle Lavaud, Gwenaëlle Gravis, Stéphanie Foulon, Florence Joly, Stéphane Oudard, Frank Priou, Igor Latorzeff, Loïc Mourey, Michel Soulié, Remy Delva, Ivan Krakowski, Brigitte Laguerre, Christine Théodore, Jean Marc Ferrero, Philippe Beuzeboc, Muriel Habibian, Frédéric Rolland, Gael Deplanque, Damien Pouessel, Sylvie Zanetta, Jean François Berdah, Jerome Dauba, Marjorie Baciuchka, Christian Platini, Claude Linassier, Nicole Tubiana-Mathieu, Jean Pascal Machiels, Claude El Kouri, Alain Ravaud, Etienne Suc, Jean Christophe Eymard, Ali Hasbini, Guilhem Bousquet, Stéphane Culine, Jean-Marie Boher, Gabrielle Tergemina-Clain, Clémence Legoupil, Karim Fizazi  European Urology  Volume 73, Issue 5, Pages 696-703 (May 2018) DOI: 10.1016/j.eururo.2017.09.022 Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 1 Prostate-specific antigen (PSA) declines after docetaxel used in first- or second-line therapy for patients with metastatic castration-resistant prostate cancer. (A) Patients who have progressed after androgen deprivation therapy alone given for castration-naïve prostate cancer. (B) Patients who have progressed after androgen deprivation therapy plus docetaxel given for castration-naïve prostate cancer. European Urology 2018 73, 696-703DOI: (10.1016/j.eururo.2017.09.022) Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 2 Biochemical progression-free survival after initiation of docetaxel treatment used as first-line therapy for metastatic castration-resistant prostate cancer. Androgen deprivation therapy (ADT) arm: patients treated with upfront ADT alone for metastatic castration-naive prostate cancer; ADT plus docetaxel arm: patients treated with upfront ADT plus docetaxel for metastatic castration-naive prostate cancer. European Urology 2018 73, 696-703DOI: (10.1016/j.eururo.2017.09.022) Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 3 Prostate-specific antigen (PSA) decline with next generation androgen receptor-axis inhibitors (abiraterone or enzalutamide) used as first- or second-line treatments for metastatic castration-resistant prostate cancer in patients originally treated upfront with androgen deprivation therapy plus docetaxel for metastatic castration-naive prostate cancer. European Urology 2018 73, 696-703DOI: (10.1016/j.eururo.2017.09.022) Copyright © 2017 European Association of Urology Terms and Conditions